NASDAQ:LUCD Lucid Diagnostics (LUCD) Stock Price, News & Analysis $1.28 -0.01 (-0.39%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.29 +0.00 (+0.31%) As of 05/2/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lucid Diagnostics Stock (NASDAQ:LUCD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lucid Diagnostics alerts:Sign Up Key Stats Today's Range$1.28▼$1.3150-Day Range$1.09▼$1.6552-Week Range$0.68▼$1.80Volume705,989 shsAverage Volume473,982 shsMarket Capitalization$135.42 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingBuy Company OverviewLucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Read More… Lucid Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreLUCD MarketRank™: Lucid Diagnostics scored higher than 38% of companies evaluated by MarketBeat, and ranked 379th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingLucid Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLucid Diagnostics has only been the subject of 3 research reports in the past 90 days.Read more about Lucid Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.84) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lucid Diagnostics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lucid Diagnostics is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Lucid Diagnostics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.00% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lucid Diagnostics has recently increased by 16.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLucid Diagnostics does not currently pay a dividend.Dividend GrowthLucid Diagnostics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.00% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lucid Diagnostics has recently increased by 16.79%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Lucid Diagnostics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lucid Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.80% of the stock of Lucid Diagnostics is held by insiders.Percentage Held by Institutions74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lucid Diagnostics' insider trading history. Receive LUCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address LUCD Stock News HeadlinesLucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025April 30, 2025 | prnewswire.comLucid Diagnostics’ EsoGuard DNA Test shows cancer detection efficacy in studyApril 26, 2025 | markets.businessinsider.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.May 5, 2025 | Brownstone Research (Ad)Lucid Diagnostics Reports Positive Data for EsoGuard in Study of Asymptomatic PatientsApril 24, 2025 | theglobeandmail.comLucid reports encouraging results from EsoGuard studyApril 24, 2025 | msn.comNCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERDApril 24, 2025 | prnewswire.comLucid Diagnostics price target raised to $7.50 from $7 at AscendiantApril 22, 2025 | markets.businessinsider.comLucid Diagnostics Closes $16.1 Million Public OfferingApril 11, 2025 | tipranks.comSee More Headlines LUCD Stock Analysis - Frequently Asked Questions How have LUCD shares performed this year? Lucid Diagnostics' stock was trading at $0.8187 on January 1st, 2025. Since then, LUCD shares have increased by 57.0% and is now trading at $1.2850. View the best growth stocks for 2025 here. How were Lucid Diagnostics' earnings last quarter? Lucid Diagnostics Inc. (NASDAQ:LUCD) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.26) earnings per share (EPS) for the quarter. The firm had revenue of $1.04 million for the quarter. Read the conference call transcript. When did Lucid Diagnostics IPO? Lucid Diagnostics (LUCD) raised $75 million in an IPO on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Who are Lucid Diagnostics' major shareholders? Top institutional shareholders of Lucid Diagnostics include XML Financial LLC (0.20%). View institutional ownership trends. How do I buy shares of Lucid Diagnostics? Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lucid Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lucid Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Netflix (NFLX), Clean Energy Fuels (CLNE) and Baidu (BIDU). Company Calendar Last Earnings3/26/2024Today5/04/2025Next Earnings (Estimated)5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:LUCD CIK1799011 Webwww.luciddx.com Phone212-949-4319FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$7.50 Low Stock Price Target$2.00 Potential Upside/Downside+172.4%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,670,000.00 Net Margins-1,069.87% Pretax Margin-1,069.90% Return on EquityN/A Return on Assets-123.54% Debt Debt-to-Equity RatioN/A Current Ratio1.18 Quick Ratio1.14 Sales & Book Value Annual Sales$4.35 million Price / Sales31.16 Cash FlowN/A Price / Cash FlowN/A Book Value($0.47) per share Price / Book-2.73Miscellaneous Outstanding Shares105,383,000Free Float54,120,000Market Cap$135.42 million OptionableNo Data Beta1.26 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:LUCD) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.